Xeris Biopharma Holdings Inc (FRA:2B30)

Q4 2024 Xeris Biopharma Holdings Inc Earnings Call Transcript

Mar 6, 2025 / 01:30 PM GMT

Release Date Price: €3.42 (-1.61%)

Transcript 10-K8-K

Key Points

Positve

Xeris Biopharma Holdings Inc (XERS) exceeded its full-year guidance with total revenue of over $203 million, marking a 24% growth compared to the previous year.
The company reported a 28% product revenue growth for 2024, driven by strong demand for its products, particularly Recole, which saw a 118% increase in revenue.
Xeris Biopharma Holdings Inc (XERS) achieved positive adjusted EBITDA in the fourth quarter of 2024 and expects to maintain this positive trend moving forward.
The company is guiding for a 30% year-over-year revenue growth in 2025, with expected total revenue between $255 and $275 million.
Xeris Biopharma Holdings Inc (XERS) successfully completed its phase 2 study for XP 8,121 and is preparing for phase 3, indicating progress in its pipeline development.

Negative

Caveyas brand experienced a 13% decline in revenue for the full year, although the number of patients on therapy remained stable.
The company anticipates continued pressure on reimbursement and net pricing for its products, similar to what was experienced in 2024.
Research and development expenses increased by $3.2 million compared to the prior year, driven by investments in XP 8,121 and technology platforms.
Selling, general, and administrative expenses rose by 12% for the year, partly due to a one-time charge related to CEO succession and corporate restructuring.
Xeris Biopharma Holdings Inc (XERS) faces challenges in identifying and reaching the full potential patient population for its products, particularly in the hypercortisolism market.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

XERS.OQ - Xeris Biopharma Holdings Inc
Q4 2024 Xeris Biopharma Holdings Inc Earnings Call
Mar 06, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to the Zerus BioPharma 4th quarter and full year 2024 financial results. My name is Harry and I'll be your operator today. All lines are currently in listen-only mode, and there will be an opportunity for Q&A after management's prepared remarks. If you would like to enter the queue for questions, please dial star followed by 1 on your telephone keypad. I would now like to hand the call over to Alison Way, senior Vice President of Investor relations and corporate communications.

Thank you. You may proceed.

--------------------------------------------------------------------------------
Unidentified_2 [2]
------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.